Backs India’s sovereign AI security platform ahead of IPO

• Innefu Labs achieves Series B Capital to Scale Sovereign National Security AI
• Innefu labs on pathway for IPO
• The transaction occurs amid accelerating domestic procurement cycles driven by the Government of India’s Atmanirbhar Bharat mandates

SINGAPORE, June 5, 2026 /PRNewswire/ — Panthera Growth Partners (PGP), a Singapore-based growth equity firm, today announced a USD 30 million investment in Innefu Labs, India’s leading artificial intelligence company in the space of National Security and creating indigenous platforms & multi-modal fusion systems currently deployed across defense, intelligence, law enforcement, revenue intelligence, and large enterprise clients. The capital injection, completed through a combination of primary and secondary transactions from Panthera’s second fund, positions Innefu for an IPO and accelerates its push into international markets after Innefu’s initial successful forays in Middle East.

The investment comes as India’s sovereign defense initiatives drive sharply increased domestic procurement of critical security technologies. This is evident from Innefu’s momentum in a growing pool of USD 10 million + contracts spanning defense, intelligence, law enforcement, and revenue intelligence operations.

The proceeds will fund Innefu’s next phase of global market expansion, alongside deep-tech research and development anchored in its AI-first, sovereign capabilities. This includes advancing its proprietary Agentic AI platform, establishing a dedicated Physical AI (robotics) wing, and developing sovereign AI infrastructure with secure, domain-specialized language models built for high-trust environments.

Tarun Wig, Co-Founder and CEO of Innefu Labs, stated: “When we started Innefu, our vision was clear: India should never have to depend on external technologies to secure its people, its institutions, or its digital future. Over the last fifteen years, we have transformed that vision into reality, building indigenous AI-powered platforms that protect critical national assets, empower decision-makers, and strengthen the country’s security ecosystem.

We now intend to scale our innovations faster, deepen our investments in advanced AI and further enhance our autonomous decision-support systems. We believe the next wave of technological leadership will belong to nations that own their intelligence capabilities, and Innefu is committed to ensuring that India stands at the forefront of that transformation.

What excites us most is that we are still at the beginning of our story. The foundations have been laid, the talent is in place, and the mission has never been clearer. With this new chapter, we are not just building a company, we are helping build the technological backbone of a secure, self-reliant, and AI-powered India for generations to come.”

Shilpa Kulkarni, Founder and Managing Partner of Panthera Growth Partners, stated:  “Innefu has built native, AI-powered software that solve critical challenges in national defense and enterprise security infrastructure. Our investment decision is based on their proprietary technology, deep domain expertise, and a proven track record in high-stakes, mission-critical environments. We are partnering with Innefu to support their growth ambitions as they prepare for public markets.”

Operational Footprint and Market Context

The domestic security technology market involves complex technical requirements historically met by international defense vendors.

Innefu’s deployments include several national scale AI intelligence fusion centres including:

• India’s first National Terrorism Data Fusion Centre,
• Southeast Asia’s largest operational Intelligence Fusion Centre,
• Revenue Intelligence Fusion Platforms,
• Predictive Policing Platforms,
• Indigenous open-source intelligence (OSINT) and Deep Web Fusion Platform for Law Enforcement & Defense Agencies.

Abhishek Sharma, Co-Founder and CTO of Innefu Labs, added: “For over a decade, we’ve solved mission-critical challenges for defense, intelligence, and investigative agencies. As governments worldwide move toward AI-driven decision-making, our mission is to build trusted, AI-first indigenous platforms that strengthen national security and keep critical data & platforms sovereign. This funding accelerates our next chapter: advancing our Agentic AI capabilities, venturing into Physical AI and robotics, and expanding globally, building the full sovereign AI stack that high-trust environments demand”

Panthera’s second fund, backed by institutional investors from India, the European Union, and the United States, focuses on growth-stage companies with established product-market fit, deploying an average capital allocation of USD 20 million per company across India and Southeast Asia. The firm’s historical portfolio across its fund vehicles includes allocations in FoxTale, OfBusiness, Zivame, Travelstack Tech, EMotorad, Flipspaces etc.

About Panthera Growth Partners

Panthera Growth Partners is a growth equity investment firm investing in next generation technology leveraged businesses. We are differentiated by our deep network of operational resources and industry relationships, systematic value creation process, and strong execution capability.

For more information, visit www.pantheragp.com.

About Innefu Labs

Founded in 2010, Innefu is an AI driven company in the field of National and Cyber Security. The company was started with a clear focus to carry out high Tech R&D which fuels innovation and leads to products which can capture the global market and be the cornerstone of the economy of the country. Innefu is a fully indigenous Artificial Intelligence company committed to strengthening National and Cyber Security. With more than 100+ installations across Indian Subcontinent, Middle East and South East Asia, the company is today a de-facto leader in developing and deploying AI for National and Cyber Security.

The company with its own range of products serves a diverse client base including Defense and Intelligence organizations, Law Enforcement Agencies, Financial Intelligence Units, BFSI as well as top Fortune 500 companies. Having worked with some of the most sensitive organizations the company has a deep understanding of handling sensitive and critical installations.

For more information, visit www.innefu.com.

Singapore-founded AI company scales enterprise AI agents across new industries and global markets

SINGAPORE, June 5, 2026 /PRNewswire/ — Rezonate, the Singapore-founded AI engagement company, today announced a US$5 million fundraise to support its expansion into the United States and accelerate the next phase of its global growth in enterprise AI.

The announcement marks a significant milestone in the company’s evolution, alongside the launch of its new brand identity, Rezonate, reflecting its broader mission to help enterprises across industries transform customer and workforce engagement through AI agents. The new name marks a deeper shift – a belief that the next leap in enterprise AI isn’t just about responding faster, but about connecting in a way that’s felt, understood, and remembered.

Founded in Singapore, Rezonate has built and deployed AI solutions across healthcare, insurance, financial services, sports and other enterprise sectors across Asia. The company specializes in AI agents for customer engagement, enabling organizations to move beyond AI experimentation into scalable deployment, helping automate engagement workflows, improve service delivery, automate seamless customer support, drive conversions with personalized outreach, cut operating costs, and scale operational efficiency across regulated and complex environments.

“The rebrand to Rezonate reflects how the company has evolved,” said Peiru Teo, CEO of Rezonate. “We were forged over a decade in healthcare – one of the most human and high‑stakes industries there is – but what we are seeing globally is that enterprises across every industry face the same engagement and operational challenges. Rezonate represents our ambition to help organizations deploy AI agents for customer engagement that are intelligent, scalable, and human-centered globally.”

The US$5 million fundraise will support Rezonate’s expansion into the United States, strengthen commercial partnerships, and accelerate the development of its AI agent platform.

Rezonate’s evolution reflects a broader shift in the market: enterprises are increasingly adopting AI systems that transform conversations and existing data into actionable outcomes, enabling revenue growth, stronger customer retention, and improved service delivery at scale.

About Rezonate

Rezonate is a Singapore-founded AI company building AI agents for customer engagement across healthcare, insurance, financial services, sports and other enterprise sectors. Its platform enables organizations to automate engagement workflows, improve service delivery, drive revenue growth through more effective customer engagement, and scale operational efficiency across regulated and complex environments. Learn more at https://getrezonate.com/.

SHANGHAI, June 5, 2026 /PRNewswire/ — Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for inflammatory bowel disease (IBD). 9MW5211 is the first candidate drug for its target to enter clinical stage globally.

9MW5211 is a highly specific, depleting, and innovative antibody independently developed by Mabwell, designed to precisely intervene in the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells act as the core driving factors in the occurrence and development of various autoimmune diseases. The target molecule of 9MW5211 is specifically expressed on the surface of pathogenic immune cells and serves as a vital biological marker of their abnormal activation. By selectively recognizing and depleting this population of pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby delaying disease progression and ameliorating clinical symptoms.

Through multiple rounds of molecular engineering optimization, 9MW5211 has demonstrated excellent target selectivity. While achieving efficient blockade, it significantly mitigates the risk of non-specific binding, ensuring deep depletion of pathogenic cells highly expressing the target protein. Such a unique mechanism of action is expected to not only bring deeper disease remission but also potentially support an extended dosing interval, thereby enhancing patient compliance and quality of life.

Preclinical study results have demonstrated that 9MW5211 exhibits significant therapeutic potential in various mouse models of autoimmune diseases, suggesting its future clinical application may cover multiple major indications. Safety evaluations conducted in cynomolgus monkey models have shown a favorable safety profile.

Previously, 9MW5211 has received clearance from FDA to conduct clinical trials for IBD in the US. Its clinical trial applications for multiple indications, including multiple sclerosis (MS), have been accepted by the NMPA. Clinical trial applications for more indications are also being actively advanced.

About Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease is a chronic, relapsing, immune-mediated disorder of the gastrointestinal tract, which primarily includes ulcerative colitis and Crohn’s disease. The number of IBD cases globally has been steadily increasing. Epidemiological studies indicate that the number of newly diagnosed IBD patients worldwide rose from 5.90 million in 2019 to 7.00 million in 2023, representing a compound annual growth rate (CAGR) of 4.4%. The number of newly diagnosed IBD patients globally is projected to reach 11.50 million by 2032, with a CAGR of 5.6% from 2023 to 2032

About Multiple Sclerosis (MS)

Multiple sclerosis is a chronic autoimmune disease characterized by inflammatory damage to the protective myelin sheaths surrounding the nerves of the brain and spinal cord. The number of MS patients globally increased from 2.80 million cases in 2020 to 3.00 million cases in 2024, and is projected to reach approximately 3.50 million cases by 2035. In China, the number of MS patients increased from 32,800 cases in 2020 to 33,900 cases in 2024, and is expected to reach 35,500 cases by 2035.

About Mabwell

Mabwell (688062.SH, 02493.HK) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.